 |
 |
 |
 |
 |
 |
 |
|
|
|
|||||||||
|
|||||||||||
Professor and Chair of Pharmacy Practice, College of Pharmacy, Oregon State University/Oregon Health & Science University, Portland Campus at OHSU, 3303 SW Bond Ave., Portland, OR 97239, fax 503/494-8797, itom{at}ohsu.edu
Reprints: Dr. Ito
OBJECTIVE: To present an overview of antisense technology and to review and assess available literature on the chemistry, pharmacology, pharmacokinetics, drug interactions, preclinical and clinical studies, dosing, and adverse events of ISIS 301012 in the treatment of hyperlipidemia.
DATA SOURCES: PubMed database searches were conducted from 1966 to May 2007 using the search terms ISIS 301012, antisense, oligonucleotide, hypercholesterolemia, hyperlipidemia, and apolipoprotein B. Bibliographies of relevant review articles and information from the manufacturer were reviewed for additional references.
STUDY SELECTION AND DATA EXTRACTION: Available English-language literature, including abstracts, preclinical, and clinical trials, review articles, and scientific presentations were examined.
DATA SYNTHESIS: Apolipoprotein B is an important structural protein on the surface of atherogenic lipoproteins such as remnant very-low-density lipoprotein and low-density lipoprotein and facilitates the clearance of these particles from the circulation by binding to the low-density lipoprotein receptor. Overproduction of apolipoprotein B or reduced receptor-mediated clearance of lipoproteins leads to elevated serum cholesterol levels and premature atherosclerosis. ISIS 301012 is an antisense oligonucleotide that inhibits apolipoprotein B production by binding directly to and reducing the expression of apolipoprotein B messenger RNA. In a clinical trial, ISIS 301012 50-400 mg administered weekly via subcutaneous injection for 4 weeks reduced apolipoprotein B by 14.3-47.4% and low-density lipoprotein cholesterol by 5.9-40% at 55 days. The most frequent adverse event was injection-site erythema that resolved spontaneously. Studies are ongoing to further define the safety, efficacy, and pharmacokinetics of ISIS 301012 as add-on therapy in patients with heterozygous and homozygous familial hypercholesterolemia. No pharmacokinetic interactions have been demonstrated with ezetimibe and simvastatin.
CONCLUSIONS: ISIS 301012 is the first agent to enter clinical trials utilizing an antisense mechanism for reducing the production of apolipoprotein B. Further studies are needed to verify its safety, efficacy, and position of therapy in the dyslipidemic patient.
Key Words: antisense, apolipoprotein B-100, hypercholesterolemia, hyperlipidemia, ISIS 301012, ologonucleotide
Published Online, September 11, 2007. www.theannals.com, DOI 10.1345/aph.1K065
 |
 |
 |
 |
 |
 |
 |
